Business Wire: First patient enrolled in CARE-HK in HF to evaluate role of Veltassa® (patiromer) in enabling RAASi treatment

April 29, 2021

Vifor Pharma announced that the first patient has been enrolled in the large scale registry CARE-HK in HF (cardiovascular and renal treatment in HF patients with or at high risk for HK). This non-interventional clinical study aims to better understand renin-angiotensin-aldosterone system inhibitors (RAASi) treatment decisions in clinical practice, potential barriers to achieving optimal guideline-directed care in HF patients with or at high risk for HK, and to assess how Veltassa® may be used in the management of this patient population.

Dr. Mikhail Kosiborod, cardiologist and Vice President of Research at Saint Luke's Health System, explains how the registry is the first of its kind and how it will help optimize the quality of patient care.

Read the full Business Wire article: First patient enrolled in CARE-HK in HF to evaluate role of Veltassa® (patiromer) in enabling RAASi treatment

Related Content

Legacies of Excellence: Mikhail Kosiborod, MD, Officially Bestowed the Ben McCallister, MD, Endowed Chair in Cardiovascular Research
Saint Luke’s honored two of its visionary leaders this week as Mikhail Kosiborod, MD, was formally recognized as the inaugural Ben McCallister, MD, Endowed Chair in Cardiovascular Research.
Business Wire: Medical Society Urges Use of Ultrasound Contrast Agents and Supports Safety Record
Dr. Michael Main explains how the use of UCAs is proven to be safe and can help patients avoid unnecessary downstream tests.
MedwireNews: Direct ‘decongestion’ effect shown for empagliflozin in HF
MedwireNews explains the findings of the randomized EMBRACE-HF trial by Dr. Mikhail Kosiborod and his colleagues.